Holen Sie sich die Stockscreener-App
26.45
1.12%
-0.30
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data - Insider Monkey
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 375,784 Shares of Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares - MarketBeat
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out - The Motley Fool
HC Wainwright Analysts Increase Earnings Estimates for ROIV - MarketBeat
Is Roivant Sciences Ltd. stock undervalued right now2025 Short Interest & AI Based Buy and Sell Signals - mfd.ru
Can Roivant Sciences Ltd. lead its sector in growthLayoff News & Detailed Earnings Play Alerts - mfd.ru
EV Market: What is IROQs debt to equity ratioJuly 2025 Snapshot & Verified Momentum Stock Watchlist - baoquankhu1.vn
Roivant Sciences (NASDAQ:ROIV) Insider Sells $8,985,003.27 in Stock - MarketBeat
Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Why Roivant Sciences Ltd. (87S) stock appeals to dividend investors2025 Performance Recap & Expert Curated Trade Ideas - mfd.ru
Candriam S.C.A. Increases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock price target raised to $33 from $26 at H.C. Wainwright - Investing.com Australia
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV)Here's Why - Finviz
Citi raises Roivant Sciences stock price target to $35 from $26 - Investing.com Australia
Citi raises Roivant Sciences stock price target to $35 from $26 By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs - Investing.com India
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why - Insider Monkey
Roivant Sciences Earnings Call Highlights Brepocitinib Surge - TipRanks
Roivant Sciences stock hits all-time high at 26.35 USD By Investing.com - Investing.com Nigeria
Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings) - Benzinga
Roivant Sciences stock hits all-time high at 26.35 USD - Investing.com
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum - Yahoo Finance
Looking At The Narrative For Roivant Sciences ROIV After 2026 Catalyst And Litigation Shifts - Yahoo Finance
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next - TechStock²
Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?Lumentum Holdings (NASDAQ:LITE), Oshkosh (NYSE:OSK), Roivant Sciences (NASDAQ:ROIV), Regal Rexnord (N - Benzinga
Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund - MarketBeat
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Canada
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year HighStill a Buy? - MarketBeat
Roivant Sciences Q3 Earnings Call Highlights - MarketBeat
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Priovant announces positive phase 2 results for brepocitinib in cutaneous sarcoidosis (Cs) - marketscreener.com
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c - StreetInsider
0.87%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):